Pivotal (Spain)

Recent papers from Pivotal (Spain)

1. State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectivesExpert Opinion on Biological Therapy · 2025
2. Urinary Metabolic Distinction of Niemann–Pick Class 1 Disease through the Use of Subgroup DiscoveryMetabolites · 2023
3. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational StudySHILAP Revista de lepidopterología · 2022
4. Prevalence of Advanced Parkinson’s Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE StudyBrain Sciences · 2021
5. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first‐line metastatic renal carcinoma (SUNRISES study)BJU International · 2020
6. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment RationaleCancers · 2019
7. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)EBioMedicine · 2018
8. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapyMelanoma Research · 2018
9. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor PrognosisEBioMedicine · 2018
10. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patientsTherapeutic Advances in Medical Oncology · 2018
11. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstractsJournal of Translational Medicine · 2018
12. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerNature Communications · 2017
13. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCJNCI Journal of the National Cancer Institute · 2017
14. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerScientific Reports · 2015
15. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerOncotarget · 2015
16. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMelanoma Research · 2015
17. Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialJAMA Oncology · 2015
18. Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC TrialFuture Oncology · 2015